RxDoctor Payments Data

Jeffrey Bigler, MD

Gastroenterology · Tulsa, OKNPI 1164419362

Payments from drug & device makers

$1,320in general payments, 2019–2025

Across 75 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$492
  • AbbVie$340
  • Fujifilm Healthcare Americas Corporation$120
  • Pfizer$104
  • Gilead$54
  • Bristol Myers Squibb$42
  • plus $167 from 9 others

What the payments were for

  • Food & beverage$1,17589%
  • Education$242%
  • Gifts$1209%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,320 in reported general payments places this provider in the 25th percentile of 133 gastroenterology providers in Oklahoma.

See all gastroenterology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$223,783
Medicare patients
417
Services billed
8,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab54$1,423,290
XifaxanRifaximin12$35,826
ClenpiqSod Picosulf/Mag Ox/Citric Ac62$10,802
Omeprazole299$5,730
Dexlansoprazole DrDexlansoprazole16$5,100
Ursodiol15$3,544
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates43$2,257
Budesonide DrBudesonide16$1,484
Tenofovir Disoproxil Fumarate11$1,462
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine53$1,170
Pantoprazole Sodium80$1,170
CholestyramineCholestyramine (With Sugar)16$1,092
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl68$961
Mesalamine ErMesalamine12$675
Ondansetron OdtOndansetron38$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$492$1,423,29054 claims
Ferring Pharmaceuticals Inc.Clenpiq$18$10,80262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 133 gastroenterology providers in Oklahoma.

Other gastroenterology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →